Frank Mathias, Oxford Biomedica CEO
September 20, 2023 11:34 AM EDTUpdated September 21, 04:10 AM
People
Manufacturing

Ox­ford Bio­med­ica piv­ots by lay­ing off 200 peo­ple, ac­quir­ing ABL Eu­rope amid de­clin­ing to­tal rev­enues

Anna Brown

News Reporter

In its bid to be­come a pure-play cell and gene ther­a­py CD­MO, Ox­ford Bio­med­ica is lay­ing off 200 staff mem­bers in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times